Their world
PharmEasy's next chapter depends on turning a balance-sheet reset into repeatable operating leverage.
Debt is falling, EBITDA has crossed into positive territory, and IPO readiness is back on the agenda. The CEO question is no longer whether the turnaround is visible. It is which operating workflow can make that progress durable without restarting the infrastructure cycle.
Their pressure
The recovery is measurable. So is the cost of losing focus.
The bridge
Choose one workflow where control and cost can move together.
Meridian AI embeds with your team and ships production-grade LLM and agent systems — on your data, with human-in-the-loop controls — in six weeks, not six quarters. For PharmEasy, that starts with one review-heavy operating workflow: retrieval over existing data, a function-calling agent wired into current services, and a human approval path. No model training, rip-and-replace, or new infrastructure to run. That is how “healthcare simplified” can apply behind the scenes as well as at the customer edge.
Three markers, one operating mandate
One proof
A bounded engagement, accountable to one number.
Every engagement targets one measurable operating metric per quarter, and we don't scale the retainer until that metric moves.
One working session
Map one cost surface in the turnaround.
Twenty minutes to identify the workflow, define its current handling cost, and set the human-review boundary before any build begins.
See the 20-minute teardown for PharmEasy